Biotech Values

[Bulbaman]

>>How do you know the disease doesn't typically recur in the third year in this patient population?

I don’t know. What I do know is, based on the cited ADXS anal cancer drug efficacy, the respected Radiation Therapy Oncology Group (RTOG) has agreed to run a pivotal Phase 2/3 anal cancer trial in collaboration with Advaxis. Also, I trust that ADXS management isn’t just hyping their stock by highlighting their anal cancer results. Of course, it’s possible I’m being naive.